To include your compound in the COVID-19 Resource Center, submit it here.

Zydelig idelalisib regulatory update

The European Commission approved an MAA from Gilead for Zydelig idelalisib to treat chronic lymphocytic leukemia

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE